ClinicalTrials.gg
CompletedNCT04564872Updated Dec 12, 2022

HSK7653 Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus

A Phase 3 interventional study of HSK7653 10 mg Q2W and HSK7653 25 mg Q2W in Diabetes Mellitus, Type 2, sponsored by Sichuan Haisco Pharmaceutical Group Co., Ltd. Completed at 2 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-12-12.

Sponsored by Sichuan Haisco Pharmaceutical Group Co., Ltd (part of Haisco Pharmaceutical Group Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
465
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 909 studies in Diabetes Mellitus, Type 2 with a site in China — 205 open to participants now, 228 under way, 46 of them phase 3. Diabetes Mellitus, Type 2 · China.

Enrollment
185th of 767
465 · median 199
Started
2020
with 49 others
Phase 3
207 of 909
38 open now
Registered
437th of 909
by date

Among the 909 studies in Diabetes Mellitus, Type 2 with a site in China, this one is the 185th largest by enrollment of the 767 interventional ones that give a count, is one of 50 that started in 2020, is one of 207 in phase 3, and was the 437th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

205 of the 909 studies in Diabetes Mellitus, Type 2 with a site in China are open now. Recruiting first, the newest first:

200 more — sign in →

All 205 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 909 studies in Diabetes Mellitus, Type 2 with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to assess the efficacy of HSK7653 (as an add-on to metformin) compared with linagliptin after 24 weeks, and the safety (up to 52 weeks) of HSK7653 in Chinese patients with Type 2 Diabetes who have inadequate glycemic control on diet/exercise therapy and metformin agent monotherapy.

Read the detailed description

The treatment period is composed of a 24-week double-blind period (week 1-24) and a 28-week open-label period (week 25-52). During the double-blind period, participants will receive 10 mg or 25 mg dose of HSK7653, or linagliptin, and with matching placebo respectively. During the open-label period, all participants will receive 25 mg dose of HSK7653. All participants will receive a stable dose of metformin therapy in both the double-blind period and the open-label period.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 and ≤ 75 years, Male and female patients;
  • Type 2 diabetes mellitus;
  • Insufficient glycaemic control with diet/exercise therapy and metformin agent monotherapy;
  • Did not receive regular long-term medication of oral hypoglycemic drugs (except metformin) or insulin within 1 year prior to ;
  • in the range of ≥7.5 to ≤11.0% at screening;
  • FPG \< 15 mmol/L at screening;
  • (Body Mass Index) in the range of ≥ 18.0 kg/m² to ≤ 35.0 kg/m² at screening.

Exclusion criteria

Exclusion Criteria:

  • Diabetic ketoacidosis, hyperglycemia hypertonic state, serious complications of diabetes, myocardial infarction, stroke within 6 months prior to ;
  • History of severe endocrine disease, uncured cancer, acute pancreatitis prior to informed consent;
  • Current hemoglobinopathy, uncontrolled hypertension, serious nephropathy or hepatopathy prior to informed consent;
  • Serious gastrointestinal disease within 2 weeks prior to informed consent;
  • Serious infection, trauma, and surgery within 3 months prior to informed consent;
  • History of treatment with Dipeptidyl-Peptidase 4 (DPP-4) inhibitor, Glucose-dependent insulinotropic polypeptide (GIP) or Glucagon-like peptide-1 (GLP-1) receptor agonist;
  • Treatment with drugs that affect glucose metabolism within 8 weeks prior to informed consent;
  • (HGB) \< 10.0 g/dL(100 g/L);
  • Alcohol abuse within 6 months or drug abuse history within 5 years prior to informed consent;
  • Active infectious diseases;
  • Participation in another trial with an drug or instrument within 3 months prior to informed consent;
  • Women who are nursing or pregnant, or subjects who have planned parenthood;
  • for empagliflozin or linagliptin;
  • Other protocol-defined inclusion/exclusion criteria.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
465 participants (actual)

Study arms

  • Experimental
    HSK7653 10 mg

    Drug: HSK7653 10 mg Q2W

  • Experimental
    HSK7653 25 mg

    Drug: HSK7653 25 mg Q2W

  • Active comparator
    Linagliptin 5 mg

    Drug: Linagliptin 5 mg QD

Interventions

  • HSK7653 5 mg (2 tablets) and placebo 25 mg (1 tablet) Q2W, placebo of linagliptin 5 mg QD, oral, week 1 to week 24; HSK7653 25 mg Q2W, oral, week 25 to week 52.

  • HSK7653 25 mg (1 tablet) and placebo 5 mg (2 tablets) Q2W, placebo of linagliptin 5 mg QD, oral, week 1 to week 24; HSK7653 25 mg (1 tablet) Q2W, oral, week 25 to week 52.

  • Linagliptin 5 mg QD, placebo of HSK7653 25 mg (1 tablet) and 5 mg (2 tablets) Q2W, oral, week 1 to week 24; HSK7653 25 mg Q2W, oral, week 25 to week 52.

06

What researchers measure

Primary outcomes

  1. HbA1c Change From Baseline at Week 24

    Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24

    Time frame: Baseline and week 24

Secondary outcomes

  1. Incidence of Treatment-Emergent Adverse Events

    The incidence of Treatment-Emergent Adverse Events over time (at week 24 and week 52)

    Time frame: Baseline, week 24 and week 52

  2. Percentage of Patients With HbA1c <7.0%

    Time frame: Baseline, week 24 and week 52

  3. Percentage of Patients With HbA1c <6.5%

    Time frame: Baseline, week 24 and week 52

  4. FPG Change From Baseline at Week 24 and Week 52

    Time frame: Baseline , week 24 and week 52

  5. 2h-PPG Change From Baseline at Week 24 and Week 52

    Time frame: Baseline, week 24 and week 52

  6. Weight Change From Baseline at Week 24 and Week 52

    Time frame: Baseline, week 24 and week 52

  7. Fasting C-peptide Change From Baseline at Week 24 and Week 52

    Time frame: Baseline, week 24 and week 52

  8. Insulin Sensitivity Change (Calculated by HOMA-IS) From Baseline at Week 24 and Week 52

    Time frame: Baseline, week 24 and week 52

  9. Pancreatic β-cell function Change (Calculated by HOMA-β) From Baseline at Week 24 and Week 52

    Time frame: Baseline, week 24 and week 52

  10. Percentage of Patients Required Use of Rescue Therapy or Dropout due to Hyperglycemia and Week 52

    Time frame: Baseline, week 24 and week 52

07

Study locations

2 sites
  • Peking University People's Hospital
    Beijing, Beijing 100044, China
  • Inner Mongolia Baogang Hospital
    Baotou, Inner Mongolia, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2020 to primary completion in Jan 2022, 14 months.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 14 months is below that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2020
First posted
Sep 25, 2020
StartActual
Nov 13, 2020
Primary completionActual
Jan 21, 2022
CompletionActual
Aug 29, 2022
Last update
Dec 12, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 12, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04564872
Responsible party
Sponsor
First posted
Sep 25, 2020
Start date
Nov 13, 2020
Primary completion
Jan 21, 2022
Completion
Aug 29, 2022
Last update
Dec 12, 2022

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HSK7653

Start the discussion